Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study (Q37429034)
Jump to navigation
Jump to search
scientific article published on April 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study |
scientific article published on April 2016 |
Statements
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study (English)
Andrea P Myers
Virginia L Filiaci
Yuping Zhang
Michael Pearl
Kian Behbakht
Parviz Hanjani
Susan Zweizig
James J Burke
Gordon Downey
Paul Van Hummelen
Michael J Birrer
1 reference
1 reference
1 reference
1 reference